Shanghai Pharmaceuticals Holding Co., Ltd - 2607.HK

2607.HK Returns vs S&P 500 ⓘ

ticker	1 day return %	1 week return %	1 month return %	3 months return %	6 months return %	1 year return %	3 years return %	5 years return %	10 years return %	maximum return %
2607.HK	-0.5	-0.5	-5.9	-2.6	3.6	16.2	-22.9	-22.1	-27.9	1049.1
S&P 500	1.0	1.5	1.1	2.3	8.9	23.6	33.8	80.6	196.5	33856.2

Compare 2607.HK with other assets →

Returns Charts ⓘ

Interactive Price Chart

Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline

Real-time Full Quote

Attribute	Value
symbol	2607.HK
name	Shanghai Pharmaceuticals Holding Co., Ltd
price	12.18
changes percentage	-0.4902
change	-0.06
day low	12.18
day high	12.34
year high	14.7
year low	10.04
market cap	61200448956
price avg 50	12.8104
price avg 200	11.936
exchange	HKSE
volume	2005042
avg volume	3431196
open	12.2
previous close	12.24
eps	1.15
pe	10.59
earnings announcement	2025-03-26T10:59:00.000+0000
shares outstanding	5024667402
timestamp	2025-01-20 08:08:32

Financial Statements ⓘ

We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.

Overall Annual Financial Health: 36.0%

Overall Quarterly Financial Health: 31.7%

Income Statements ⓘ

• Annual Income Statement

Note: The years below are fiscal years in accounting.

	2023	2022	Y/Y change %
0000000000
revenue	260295088942	231981299764	12.21
gross profit	30929478475	30486376677	1.45
gross profit ratio	0.12	0.13	-9.58
research and development expenses	2204033687	2112197580	4.35
operating expenses	23262243771	21705375123	7.17
interest income	387819883	438297667	-11.52
interest expense	1663554793	1689278922	-1.52
ebitda	10904982354	12442470084	-12.36
ebitdaratio	0.04	0.05	-19.05
operating income	7667234704	9014650389	-14.95
operating income ratio	0.03	0.04	-24.20
net income	3767999581	5617152003	-32.92
net income ratio	0.01	0.02	-40.22
eps	1.02	1.61	-36.65

Overall Score of Annual Income Statement

0.38 out of 1

Detailed Analysis

• 📈 Positive Indicators

  Revenue Growth: revenue increased to 260,295 million in 2023 from 231,981 million in 2022 representing a change of 12.21%. This indicates a sales growth, which is a positive sign for the company.

  Gross Profit: Gross Profit increased to 30,929 million in 2023 from 30,486 million in 2022 representing a change of 1.45%. This indicates a sales profitability growth, which is a positive sign for the company.

  Research and Development (R&D) Expenses: R&D Expenses increased to 2,204 million in 2023 from 2,112 million in 2022 representing a change of 4.35%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.

• 📉 Negative Indicators

  Operating Expenses: Operating Expenses increased to 23,262 million in 2023 from 21,705 million in 2022 representing a change of 7.17%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.

  EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 10,905 million in 2023 from 12,442 million in 2022 representing a change of -12.36%. The decrease in EBITDA indicates declined operational efficiency and profitability.

  Operating Income: Operating income decreased to 7,667 million in 2023 from 9,015 million in 2022 representing a change of -14.95%. The decrease in operating income indicates worse operational performance and decreased profitability.

  Net Income: Net income decreased to 3,768 million in 2023 from 5,617 million in 2022 representing a change of -32.92%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.

  Earnings per Share (EPS): EPS increased to 1.02 in 2023 from 1.02 in 2022 representing a change of -36.65%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.

• Quarterly Income Statement

Note: The years below are fiscal years in accounting.

	2024Q3	2024Q2	Q/Q change %
0000000000
revenue	70215588223	69260358039	1.38
gross profit	7009091309	8050479347	-12.94
gross profit ratio	0.1	0.12	-14.12
research and development expenses	511121713	603573735	-15.32
operating expenses	5171221249	5475490580	-5.56
interest income	106514063	102433823	3.98
interest expense	585811845	329312513	77.89
ebitda	2408168432	2734632873	-11.94
ebitdaratio	0.03	0.04	-13.14
operating income	1837870059	2416214630	-23.94
operating income ratio	0.03	0.03	-24.97
net income	1112266758	1399633819	-20.53
net income ratio	0.02	0.02	-21.61
eps	0.3	0.37	-18.92

Overall Score of Quarterly Income Statement

0.25 out of 1

Detailed Analysis

• 📈 Positive Indicators

  Revenue Growth: revenue increased to 70,216 million in 2024Q3 from 69,260 million in 2024Q2 representing a change of 1.38%. This indicates a sales growth, which is a positive sign for the company.

  Operating Expenses: Operating Expenses decreased to 5,171 million in 2024Q3 from 5,475 million in 2024Q2 representing a change of -5.56%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.

• 📉 Negative Indicators

  Gross Profit: Gross Profit decreased to 7,009 million in 2024Q3 from 8,050 million in 2024Q2 representing a change of -12.94%. This indicates a sales profitability decline, which is a negative sign for the company.

  Research and Development (R&D) Expenses: R&D Expenses decreased to 511 million in 2024Q3 from 604 million in 2024Q2 representing a change of -15.32%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.

  EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 2,408 million in 2024Q3 from 2,735 million in 2024Q2 representing a change of -11.94%. The decrease in EBITDA indicates declined operational efficiency and profitability.

  Operating Income: Operating income decreased to 1,838 million in 2024Q3 from 2,416 million in 2024Q2 representing a change of -23.94%. The decrease in operating income indicates worse operational performance and decreased profitability.

  Net Income: Net income decreased to 1,112 million in 2024Q3 from 1,400 million in 2024Q2 representing a change of -20.53%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.

  Earnings per Share (EPS): EPS increased to 0.3 in 2024Q3 from 0.3 in 2024Q2 representing a change of -18.92%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.

Balance Sheets ⓘ

• Annual Balance Sheet

Note: The years below are fiscal years in accounting.

	2023	2022	Y/Y change %
0000000000
total assets	211972533766	198134901498	6.98
total liabilities	131646440801	120132450441	9.58
total equity	80326092964	78002451057	2.98
cash and cash equivalents	30517706443	27401395968	11.37
short term investments	10152154821	9613554659	5.60
long term investments	450543882	1863616584	-75.82
total current assets	162433862348	149512870619	8.64
total non current assets	49538671418	48622030879	1.89
total current liabilities	122371879034	110691046029	10.55
total non current liabilities	9274561766	9441404411	-1.77
common stock	3703301054	3697546172	0.16
retained earnings	36129282271	32479872339	11.24
total debt	42896731147	38561432109	11.24

Overall Score of Annual Balance Sheet

0.7 out of 1

Detailed Analysis

• 📈 Positive Indicators

  Total Assets: Total Assets increased to 211,973 million in 2023 from 198,135 million in 2022 representing a change of 6.98%. Suggesting a growth in asset holdings.

  Total Equity: Total Equity increased to 80,326 million in 2023 from 78,002 million in 2022 representing a change of 2.98%. This indicates an increase in shareholders' equity.

  Cash And Cash Equivalents: Cash And Cash Equivalents increased to 30,518 million in 2023 from 27,401 million in 2022 representing a change of 11.37%. This indicates an increase in available liquid assets.

  Short Term Investments: Short Term Investments increased to 10,152 million in 2023 from 9,614 million in 2022 representing a change of 5.6%. This indicates an increase in short-term investment holdings.

  Total Current Assets: Total Current Assets increased to 162,434 million in 2023 from 149,513 million in 2022 representing a change of 8.64%. This indicates a better liquidity position.

  Common Stock: Common Stock increased to 3,703 in 2023 from 3,698 in 2022 representing a change of 0.16%. This indicates an increase in ownership interest.

  Retained Earnings: Retained Earnings increased to 36,129 million in 2023 from 32,480 million in 2022 representing a change of 11.24%. This indicates an accumulated profits.

• 📉 Negative Indicators

  Total Liabilities: Total Liabilities increased to 131,646 million in 2023 from 120,132 million in 2022 representing a change of 9.58%. This indicates an increase in overall liabilities.

  Total Current Liabilities: Total Current Liabilities increased to 122,372 million in 2023 from 110,691 million in 2022 representing a change of 10.55%. This indicates a higher short-term debt burden.

  Total Debt: Total Debt increased to 42,897 million in 2023 from 38,561 million in 2022 representing a change of 11.24%. This indicates an increase in overall debt burden.

• Quarterly Balance Sheet

Note: The years below are fiscal years in accounting.

	2024Q3	2024Q2	Q/Q change %
0000000000
total assets	223741345791	221335871829	1.09
total liabilities	140583833874	139107250634	1.06
total equity	83157511916	82228621194	1.13
cash and cash equivalents	33822817448	36676143387	-7.78
short term investments	8562649452	7175083287	19.34
long term investments	1818227639	3263444467	-44.29
total current assets	173787729817	171602970409	1.27
total non current assets	49953615974	49732901419	0.44
total current liabilities	129532122995	129104115224	0.33
total non current liabilities	11051710878	10003135409	10.48
common stock	3704610858	3703523491	0.03
retained earnings	36061456262	35245524607	2.31
total debt	48116366264	50856159519	-5.39

Overall Score of Quarterly Balance Sheet

0.7 out of 1

Detailed Analysis

• 📈 Positive Indicators

  Total Assets: Total Assets increased to 223,741 million in 2024Q3 from 221,336 million in 2024Q2 representing a change of 1.09%. Suggesting a growth in asset holdings.

  Total Equity: Total Equity increased to 83,158 million in 2024Q3 from 82,229 million in 2024Q2 representing a change of 1.13%. This indicates an increase in shareholders' equity.

  Short Term Investments: Short Term Investments increased to 8,563 million in 2024Q3 from 7,175 million in 2024Q2 representing a change of 19.34%. This indicates an increase in short-term investment holdings.

  Total Current Assets: Total Current Assets increased to 173,788 million in 2024Q3 from 171,603 million in 2024Q2 representing a change of 1.27%. This indicates a better liquidity position.

  Common Stock: Common Stock increased to 3,705 in 2024Q3 from 3,704 in 2024Q2 representing a change of 0.03%. This indicates an increase in ownership interest.

  Retained Earnings: Retained Earnings increased to 36,061 million in 2024Q3 from 35,246 million in 2024Q2 representing a change of 2.31%. This indicates an accumulated profits.

  Total Debt: Total Debt decreased to 48,116 million in 2024Q3 from 50,856 million in 2024Q2 representing a change of -5.39%. This indicates a reduction in overall debt burden.

• 📉 Negative Indicators

  Total Liabilities: Total Liabilities increased to 140,584 million in 2024Q3 from 139,107 million in 2024Q2 representing a change of 1.06%. This indicates an increase in overall liabilities.

  Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 33,823 million in 2024Q3 from 36,676 million in 2024Q2 representing a change of -7.78%. This indicates a decrease in available liquid assets.

  Total Current Liabilities: Total Current Liabilities increased to 129,532 million in 2024Q3 from 129,104 million in 2024Q2 representing a change of 0.33%. This indicates a higher short-term debt burden.

Cashflow Statements ⓘ

• Annual Cashflow Statement

Note: The years below are fiscal years in accounting.

	2023	2022	Y/Y change %
0000000000
net change in cash	2965917696	4396391086	-32.54
operating cash flow	5231519727	4743361181	10.29
free cash flow	2260909507	2058497402	9.83
capital expenditure	-2970610219	-2684863778.16	-10.64
depreciation and amortization	2187130822	2222440863	-1.59
deferred income tax	0	-21992130.33	100.00
stock based compensation	4568384	21992131	-79.23
accounts payables	6432413770	10081417120	-36.20
inventory	-2303791595.46	-7111704594.73	67.61
acquisitions net	-356577909.96	22467555	-1687.08
investments in property plant and equipment	-2970610219	-2684863778.16	-10.64
net cash used for investing activites	-2491872839	-12473124179.46	80.02
debt repayment	6855012546	3835804379	78.71
common stock issued	0	0	NaN
common stock repurchased	0	0	NaN
dividends paid	-3981205475.75	-3093891674.68	-28.68
net cash used provided by financing activities	231850890	12138594111	-98.09
cash at end of period	27499809001	24533891305	12.09
accounts receivables	-6432413771	-10081417120	36.20
cash at beginning of period	24533891305	20137500219	21.83

Overall Score of Annual Cashflow Statement

None

Detailed Analysis

• Quarterly Cashflow Statement

Note: The years below are fiscal years in accounting.

	2024Q3	2024Q2	Q/Q change %
0000000000
operating cash flow	0	5988903089	-100.00
free cash flow	-442094796.73	5467323687	-108.09
capital expenditure	-442094796.73	-521579401.58	15.24
depreciation and amortization	0	1248982319	-100.00
deferred income tax	0	0	NaN
stock based compensation	0	350204	-100.00
accounts receivables	0	-7868733874	100.00
accounts payables	0	0	NaN
inventory	0	1335453749	-100.00
acquisitions net	2180194	-90987959.19	102.40
investments in property plant and equipment	-442094796.73	-521579401.58	15.24
net cash used for investing activites	-1675195971.42	191445196	-975.03
debt repayment	-1803658487.8	1753169211	-202.88
common stock issued	0	0	NaN
common stock repurchased	0	0	NaN
dividends paid	-2169665307.14	-392565481.59	-452.69
net cash used provided by financing activities	-3626324104.42	512847516	-807.10
net change in cash	-3048544324	6677272217	-145.66
cash at end of period	30754658478	33803202802	-9.02
cash at beginning of period	33803202802	27125930585	24.62

Overall Score of Quarterly Cashflow Statement

None

Detailed Analysis

Earnings Transcripts ⓘ

No earnings transcripts available.

Earnings Per Share (EPS) ⓘ

Analyst Stock Recommendations ⓘ

Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.

Financial Ratios ⓘ

• Annual Financial Ratios

	2023-12-31	2022-12-31	Y/Y change %
FY
calendar year	2023	2022	NaN
revenue per share	70.46	66.61	5.78
net income per share	1.02	1.61	-36.76
operating cash flow per share	1.42	1.36	3.98
free cash flow per share	0.61	0.59	3.55
cash per share	11.01	10.63	3.59
book value per share	21.74	22.4	-2.91
tangible book value per share	16.94	17.25	-1.81
shareholders equity per share	18.55	19.26	-3.67
interest debt per share	12.06	11.56	4.37
market cap	62430581288.4	62097251115.41	0.54
enterprise value	74809605992.4	73257287256.41	2.12
pe ratio	16.57	11.05	49.88
price to sales ratio	0.24	0.27	-10.40
pocfratio	11.93	13.09	-8.84
pfcf ratio	27.61	30.17	-8.46
pb ratio	0.91	0.93	-1.61
ptb ratio	0.91	0.93	-1.61
ev to sales	0.29	0.32	-8.99
enterprise value over ebitda	6.86	5.98	14.77
ev to operating cash flow	14.3	15.44	-7.41
ev to free cash flow	33.09	35.59	-7.02
earnings yield	0.06	0.09	-33.28
free cash flow yield	0.04	0.03	9.25
debt to equity	0.63	0.58	8.87
debt to assets	0.2	0.19	3.98
net debt to ebitda	1.14	0.91	24.66
current ratio	1.33	1.35	-1.73
interest coverage	4.61	5.34	-13.63
income quality	1.39	0.68	104.66
dividend yield	0.06	0.03	155.07
payout ratio	1.06	0.28	282.29
sales general and administrative to revenue	0.01	0.01	27.54
research and ddevelopement to revenue	0.01	0.01	-7.00
intangibles to total assets	0.08	0.09	-7.40
capex to operating cash flow	0.57	0.57	0.32
capex to revenue	0.01	0.01	-1.39
capex to depreciation	1.36	1.21	12.43
stock based compensation to revenue	0.0	0.0	-81.49
graham number	20.63	26.43	-21.95
roic	0.04	0.06	-27.77
return on tangible assets	0.02	0.03	-37.76
graham net net	-4.0	-3.8	-5.28
working capital	40061983314	38821824590	3.19
tangible asset value	62571415182	60079779224	4.15
net current asset value	30787421563	29380420178	4.79
invested capital	76095400219	72929808876	4.34
average receivables	73674730291.5	65596242594	12.32
average payables	39669915684.5	46780471682.5	-15.20
average inventory	35541805347.5	30782126027.5	15.46
days sales outstanding	108.2	110.43	-2.02
days payables outstanding	44.28	93.41	-52.60
days of inventory on hand	58.38	62.42	-6.47
receivables turnover	3.37	3.31	2.06
payables turnover	8.24	3.91	110.97
inventory turnover	6.25	5.85	6.92
roe	0.05	0.08	-34.35
capex per share	0.8	0.77	4.31

• Negative

  ROE: Return on Equity (ROE) decreased to 0.05 on 2023-12-31 from 0.08 on 2022-12-31, representing a change of -34.35%. Suggesting that the company has not been generating high returns for its shareholders.

• Positive

  PE Ratio: Price-to-Earnings (P/E) Ratio increased to 16.57 on 2023-12-31 from 11.05 on 2022-12-31, representing a change of 49.88%. Indicating an increase in the relative valuation of the company's stock.

• Neutral

  Current Ratio: Current Ratio decreased to 1.33 on 2023-12-31 from 1.35 on 2022-12-31, representing a change of -1.73%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.

  Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.63 on 2023-12-31 from 0.58 on 2022-12-31, representing a change of 8.87%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.

• Quarterly Financial Ratios

	2024-09-30 Q3	2024-06-30 Q2	Q/Q change %
2607.HK
calendar year	2024	2024	NaN
revenue per share	18.95	18.65	1.63
net income per share	0.3	0.38	-20.55
operating cash flow per share	0.68	1.77	-61.39
free cash flow per share	0.49	1.63	-69.83
cash per share	11.44	11.84	-3.37
book value per share	22.45	22.35	0.42
tangible book value per share	17.76	17.65	0.61
shareholders equity per share	19.13	18.9	1.22
interest debt per share	13.15	17.1	-23.12
market cap	78352519646.7	71774285255.58	9.17
enterprise value	92646068462.7	99426265292.58	-6.82
pe ratio	17.61	12.82	37.37
price to sales ratio	1.12	1.04	7.38
pocfratio	30.88	10.92	182.67
pfcf ratio	42.92	11.87	261.67
pb ratio	1.11	1.03	7.82
ptb ratio	1.11	1.03	7.82
ev to sales	1.32	1.44	-8.34
enterprise value over ebitda	41.94	30.01	39.73
ev to operating cash flow	36.51	15.13	141.28
ev to free cash flow	50.75	16.44	208.71
earnings yield	0.01	0.02	-27.20
free cash flow yield	0.02	0.08	-72.35
debt to equity	0.68	0.9	-24.57
debt to assets	0.22	0.28	-24.44
net debt to ebitda	6.47	8.35	-22.48
current ratio	1.34	1.33	0.94
interest coverage	3.14	7.61	-58.77
income quality	2.28	4.69	-51.40
dividend yield	0.03	0.01	406.29
payout ratio	1.95	0.28	595.48
sales general and administrative to revenue	0.05	-0.01	668.61
research and ddevelopement to revenue	0.01	0.01	-7.53
intangibles to total assets	0.08	0.08	-1.34
capex to operating cash flow	0.17	0.08	119.48
capex to revenue	0.01	0.01	-16.62
capex to depreciation	0	0.84	-100.00
stock based compensation to revenue	0	0.0	-100.00
graham number	11.37	12.68	-10.33
roic	0.01	0.01	-13.36
return on tangible assets	0.01	0.01	-21.48
graham net net	-3.37	-3.75	10.25
working capital	44255606822	42498855185	4.13
tangible asset value	65775563627	65359409369	0.64
net current asset value	33203895943	33055087256	0.45
invested capital	80229583908	78475733843	2.23
average receivables	86735006010	84741018770	2.35
average payables	56692616438.5	48325393140	17.31
average inventory	36415704779.5	38147316186	-4.54
days sales outstanding	114.39	109.75	4.23
days payables outstanding	78.21	85.52	-8.54
days of inventory on hand	53.5	51.58	3.74
receivables turnover	0.79	0.82	-4.05
payables turnover	1.15	1.05	9.34
inventory turnover	1.68	1.75	-3.61
roe	0.02	0.02	-21.51
capex per share	0.12	0.14	-15.26

• Negative

  ROE: Return on Equity (ROE) decreased to 0.02 on 2024-09-30 Q3 from 0.02 on 2024-06-30 Q2, representing a change of -21.51%. Suggesting that the company has not been generating high returns for its shareholders.

• Positive

  PE Ratio: Price-to-Earnings (P/E) Ratio increased to 17.61 on 2024-09-30 Q3 from 12.82 on 2024-06-30 Q2, representing a change of 37.37%. Indicating an increase in the relative valuation of the company's stock.

  Current Ratio: Current Ratio increased to 1.34 on 2024-09-30 Q3 from 1.33 on 2024-06-30 Q2, representing a change of 0.94%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.

  Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.68 on 2024-09-30 Q3 from 0.90 on 2024-06-30 Q2, representing a change of -24.57%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.

Growth Rates ⓘ

• Annual Growth

• Quarterly Growth

Intrinsic Value (Discounted Cash Flow) ⓘ

None